Skip to main content

Table 4 Hazard ratio of treatment discontinuation in the bDMARDs-switched cases (Fine-Gray hazard competing risk regression model, adjusted by baseline age, sex, disease duration, concomitant PSL and MTX usage, starting date, and number of switched bDMARDs)

From: Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study

  Reference HR (95% CI)
Variable ABT (n = 273) ADA (n = 162) CZP (n = 91) ETN (n = 240) GLM (n = 250) IFX (n = 74) TCZ (n = 487) TOF (n = 101) P value
Lack of effectiveness 1 1.3 (0.9–1.8) 1.5 (1.0–2.2)* 1.1 (0.8–1.5) 1.0 (0.7–1.3) 1.3 (0.9–2.0) 0.6 (0.4–0.8)*** 0.8 (0.5–1.2) < 0.001
All toxic adverse events 1 1.8 (1.0–3.1) 0.8 (0.3–2.0) 0.4 (0.2–0.9)* 1.0 (0.6–1.9) 1.2 (0.5–2.7) 1.4 (0.9–2.3) 1.8 (0.9–3.5) 0.004
Non-toxic reasons 1 1.2 (0.6–2.2) 0.3 (0.1–1.1) 0.8 (0.4–1.4) 0.8 (0.4–1.5) 0.9 (0.4–2.4) 0.8 (0.5–1.3) 0.6 (0.2–1.5) 0.5
Remission 1 0.8 (0.1–5.0) 0.9 (0.1–9.2) 1.4 (0.3–6.1) 1.8 (0.4–7.7) 1.9 (0.4–10.7) 1.5 (0.4–5.4) 2.3 (0.4–13.8) 0.9
All adverse events (including lack of effectiveness and toxic adverse events) 1 2.7 (1.6–4.3)*** 2.2 (1.4–3.4)** 1.2 (0.8–2.0) 1.4 (1.0–2.1) 2.0 (1.0–3.7)* 0.9 (0.6–1.4) 1.1 (0.6–1.9) < 0.001
  1. bDMARDs biological disease-modifying antirheumatic drugs, PSL prednisolone, MTX methotrexate, HR hazard ratio, 95% CI 95% confidence interval, ABT abatacept, ADA adalimumab, CZP certolizumab pegol, ETN etanercept, GLM golimumab, IFX infliximab, TCZ tocilizumab, TOF tofacitinib
  2. *P < 0.05, **P < 0.01, ***P < 0.001